SPG601, an oral treatment candidate now in clinical testing, has been granted orphan drug status for fragile X syndrome in…
Articles by Marisa Wexler, MS
KER-0193, an oral therapy being developed as a fragile X syndrome treatment, has been awarded orphan drug and rare pediatric…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Spinogenix‘s experimental oral therapy SPG601 to…
A combination of therapeutic candidates gaboxadol and ibudilast normalized behavior and improved memory in a mouse model of fragile…
Excessive DNA repeats in the FMR1 gene — the cause of fragile X syndrome — lead to structural changes…
Screening of potential participants has begun in a Phase 2a trial that will test Nova Mentis Life Science’s NM-1001,…
PureTech Health is planning a Phase 2 clinical trial to test its lead therapeutic candidate LYT-300 — an oral…
Attention-deficit/hyperactivity disorder (ADHD) is more common among female carriers of a fragile X premutation who have more cell-to-cell variation…
KGK Science will launch a Phase 2a trial in the coming months to test NM-1001, a psilocybin microdose therapy…
Caregivers can accurately recognize signs of anxiety in people with fragile X syndrome whose ability to articulate their emotional…